Cambridge-based immuno-oncology biotechnology company that developed next-generation antibody therapies targeting the tumor microenvironment for cancer treatment, including programs targeting CD73, CD39, IL-27, and CD47
Cambridge-based immuno-oncology biotechnology company that developed next-generation antibody therapies targeting the tumor microenvironment for cancer treatment, including programs targeting CD73, CD39, IL-27, and CD47. Acquired by Coherus BioSciences in 2023.